Company intelligence / Profile preview

Lanyue Biomedical Technology (Hangzhou) Co., Ltd.

Hangzhou, Zhejiang Sheng (Province), Chinaen.lanyuetech.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Lanyue Biomedical Technology has an active clinical pipeline with at least one AAV-based gene therapy targeting VEGF/VEGF-A for metabolic or eye diseases. One program has reached IND approval, and another has advanced to Phase 2 clinical trials as of early April, 2025. Detailed clinical results are not publicly available.

Therapeutic areas: Rare DiseasesEndocrinologyOphthalmology
Modalities: AAV-based gene therapy
Industry: Biotech

Drug pipeline

1 asset

SMN gene therapy

Phase 1

Indications: Spinal muscular atrophy

Beyond the preview

Go deeper on Lanyue Biomedical Technology (Hangzhou) Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lanyue Biomedical Technology (Hangzhou) Co., Ltd..

Explore the full profile